{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:22:20Z","timestamp":1777418540699,"version":"3.51.4"},"reference-count":12,"publisher":"SAGE Publications","issue":"7-8","license":[{"start":{"date-parts":[[2003,7,1]],"date-time":"2003-07-01T00:00:00Z","timestamp":1057017600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2003,7]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To report a patient with dapsone-induced sulfone syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CASE SUMMARY:<\/jats:title>\n                    <jats:p>A 42-year-old HIV-infected African American man developed fever, lymphadenopathy, exfoliative dermatitis, hepatitis, and methemoglobinemia 4 weeks after starting dapsone. Complete resolution of symptoms and laboratory abnormalities occurred with cessation of dapsone therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DISCUSSION:<\/jats:title>\n                    <jats:p>Sulfone syndrome is not a well-known sequela of dapsone therapy. It is not dose-related, usually occurs in doses of 50\u2013300 mg\/d, all cases occur within 2 months of starting dapsone, all patients have fever, and most patients will develop rash and evidence of hepatic injury. The temporal relationship between dapsone therapy and onset of clinical symptoms and objective data led us to believe that dapsone caused sulfone syndrome in our patient. An objective causality assessment revealed that the adverse drug event was probable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Although sulfone syndrome appears to be relatively uncommon, healthcare practitioners must be aware of the potentially fatal syndrome associated with dapsone use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.1c432","type":"journal-article","created":{"date-parts":[[2003,5,23]],"date-time":"2003-05-23T13:16:51Z","timestamp":1053695811000},"page":"1044-1046","source":"Crossref","is-referenced-by-count":8,"title":["Dapsone-Induced Sulfone Syndrome"],"prefix":"10.1177","volume":"37","author":[{"given":"Kimberly B","family":"Lee","sequence":"first","affiliation":[{"name":"Kimberly B Lee PharmD BCPS, Clinical Specialist, Antimicrobial Management Team, Department of Pharmacy, Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals and Physicians, Richmond, VA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trisha B","family":"Nashed","sequence":"additional","affiliation":[{"name":"Trisha B Nashed MD, Fellow, Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University Health System\/Medical College of Virginia Hospitals and Physicians"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2003,7,1]]},"reference":[{"key":"bibr1-aph.1C432","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1981.01650010044023"},{"key":"bibr2-aph.1C432","first-page":"303","volume":"156","author":"Mohle-Boetani J","year":"1992","journal-title":"West J Med"},{"key":"bibr3-aph.1C432","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1986.00360170071011"},{"key":"bibr4-aph.1C432","doi-asserted-by":"publisher","DOI":"10.1097\/00007611-199411000-00018"},{"key":"bibr5-aph.1C432","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1970.04000080092020"},{"key":"bibr6-aph.1C432","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1982.01650190085028"},{"key":"bibr7-aph.1C432","first-page":"181","volume":"17","author":"Lowe J","year":"1949","journal-title":"Int J Leprosy"},{"key":"bibr8-aph.1C432","first-page":"59","volume":"66","author":"Rege VL","year":"1994","journal-title":"Indian J Leprosy"},{"key":"bibr9-aph.1C432","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)62394-0"},{"key":"bibr10-aph.1C432","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90667-2"},{"key":"bibr11-aph.1C432","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-94-6-777"},{"key":"bibr12-aph.1C432","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C432","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1345\/aph.1C432","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.1C432","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:07:16Z","timestamp":1777374436000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.1C432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,7]]},"references-count":12,"journal-issue":{"issue":"7-8","published-print":{"date-parts":[[2003,7]]}},"alternative-id":["10.1345\/aph.1C432"],"URL":"https:\/\/doi.org\/10.1345\/aph.1c432","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,7]]}}}